Severe gout: Strategies and innovations for effective management - 03/01/17

Doi : 10.1016/j.jbspin.2016.10.004

Eliseo Pascual ^a,^b,^⁎ , Mariano Andrés ^a,^b, Janitzia Vázquez-Mellado ^c, Nicola Dalbeth ^d
^a Sección de Reumatología, Hospital General Universitario de Alicante, Av. Pintor Baeza 12, 03010 Alicante, Spain
^b Departamento de Medicina Clínica (Reumatología), Universidad Miguel Hernández, Carretera Nacional 332 S/N, 03550, San Juan de Alicante, 03010 Alicante, Spain
^c Servicio de Reumatología, Hospital General de México, Dr. Balmis 148, Cuauhtémoc, Doctores, 06726 Ciudad de México, D.F., Mexico
^d Department of Rheumatology, Auckland District Health Board and Department of Medicine, University of Auckland, Auckland 1010, New Zealand

^⁎Corresponding author at: Sección de Reumatología, Hospital General Universitario de Alicante, Pintor Baeza 12, 03010 Alicante, Spain.Sección de Reumatología, Hospital General Universitario de AlicantePintor Baeza 12Alicante03010Spain

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Tuesday 03 January 2017
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Severe gout is characterised by frequent polyarticular flares, numerous tophi, joint damage, and musculoskeletal disability. This is a preventable condition and in many cases, represents a disease that has been insufficiently managed for years. Standard management recommendations may be insufficient for patients with severe gout; these patients frequently require intensive individualised pharmacological management with combinations of urate-lowering therapy and anti-inflammatory agents. In this article, we aim to integrate recent therapeutic advances to provide a practical framework for optimal management of severe gout.

Le texte complet de cet article est disponible en PDF.

Keywords : Severe gout, Refractory, Management, Colchicine, Allopurinol, Febuxostat, Tophus